IDH1 and acute myeloid leukemia: Other examples are ivosidenib, an isocitrate dehydrogenase-1 (IDH1) inhibitor, and enasidenib, an IDH2 inhibitor, which effectively targets relapsed or refractory acute myeloid leukaemia with IDH1/2 mutations (Cerchione et al., 2021) but that are not effective in gliomas bearing these mutations.